

# Hemophilia B - Pipeline Review, H2 2018

https://marketpublishers.com/r/H53B1CA925BEN.html

Date: September 2018

Pages: 135

Price: US\$ 2,000.00 (Single User License)

ID: H53B1CA925BEN

### **Abstracts**

Hemophilia B - Pipeline Review, H2 2018

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2018, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.

Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages



are 1, 6, 10, 1, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of



administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)

### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## **Contents**

### Introduction

Hemophilia B - Overview

Hemophilia B - Therapeutics Development

Hemophilia B - Therapeutics Assessment

Hemophilia B - Companies Involved in Therapeutics Development

Hemophilia B - Drug Profiles

Hemophilia B - Dormant Projects

Hemophilia B - Discontinued Products

Hemophilia B - Product Development Milestones

**Appendix** 



### **List Of Tables**

### LIST OF TABLES

Number of Products under Development for Hemophilia B, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd.1), H2 2018

Products under Development by Companies, H2 2018 (Contd.2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hemophilia B - Pipeline by Amarna Therapeutics BV, H2 2018

Hemophilia B - Pipeline by Bayer AG, H2 2018

Hemophilia B - Pipeline by Bioverativ Inc, H2 2018

Hemophilia B - Pipeline by Catalyst Biosciences Inc, H2 2018

Hemophilia B - Pipeline by China Biologic Products Inc, H2 2018

Hemophilia B - Pipeline by CSL Ltd, H2 2018

Hemophilia B - Pipeline by Expression Therapeutics LLC, H2 2018

Hemophilia B - Pipeline by GC Pharma, H2 2018

Hemophilia B - Pipeline by Genethon SA, H2 2018

Hemophilia B - Pipeline by LFB SA, H2 2018

Hemophilia B - Pipeline by Logicbio Therapeutics Inc, H2 2018

Hemophilia B - Pipeline by Novo Nordisk AS, H2 2018

Hemophilia B - Pipeline by OPKO Biologics Ltd, H2 2018

Hemophilia B - Pipeline by Pfizer Inc, H2 2018

Hemophilia B - Pipeline by Pharming Group NV, H2 2018

Hemophilia B - Pipeline by Promethera Biosciences SA, H2 2018

Hemophilia B - Pipeline by RegenxBio Inc, H2 2018

Hemophilia B - Pipeline by Sangamo Therapeutics Inc, H2 2018

Hemophilia B - Pipeline by Sanofi, H2 2018

Hemophilia B - Pipeline by Shire Plc, H2 2018

Hemophilia B - Pipeline by Spark Therapeutics Inc, H2 2018

Hemophilia B - Pipeline by UniQure NV, H2 2018

Hemophilia B - Dormant Projects, H2 2018



Hemophilia B - Discontinued Products, H2 2018



# **List Of Figures**

### LIST OF FIGURES

Number of Products under Development for Hemophilia B, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

#### **COMPANIES MENTIONED**

Amarna Therapeutics BV

Bayer AG

Bioverativ Inc

Catalyst Biosciences Inc

China Biologic Products Inc

CSL Ltd

**Expression Therapeutics LLC** 

GC Pharma

Genethon SA

LFB SA

Logicbio Therapeutics Inc

Novo Nordisk AS

**OPKO Biologics Ltd** 

Pfizer Inc

Pharming Group NV

Promethera Biosciences SA

RegenxBio Inc

Sangamo Therapeutics Inc

Sanofi

Shire Plc

Spark Therapeutics Inc



UniQure NV



### I would like to order

Product name: Hemophilia B - Pipeline Review, H2 2018

Product link: <a href="https://marketpublishers.com/r/H53B1CA925BEN.html">https://marketpublishers.com/r/H53B1CA925BEN.html</a>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/H53B1CA925BEN.html">https://marketpublishers.com/r/H53B1CA925BEN.html</a>